Cyclo(-RGDfK)

Description: Cyclo(-RGDfK) is a potent and selective inhibitor of integrin alphavbeta3 with IC50 of 0.94 nM. Cyclo specifically targets tumor microvasculature and cancer cells by binding to alphavbeta3 integrin on the cell surface. Target: Integrin. Smiles: NCCCC[C@@H]1NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CCCNC(N)=N)NC1=O. References: Sancey L,et al. Clustering and internalization of integrin alphavbeta3 with a tetrameric RGD-synthetic peptide. Mol Ther. 2009 May,17(5):837-4doi: 10.1038/mt.2009.29. Epub 2009 Mar Erratum in: Mol Ther. 2009 Jul,17(7):1301. [multipe author names corrected]. Erratum in: Mol Ther. 2009 Jul,17(7):1301.